Genome Management
Management criteria checks 1/4
Genome's CEO is Krinsky Hong, appointed in May 2023, has a tenure of 3.08 years. directly owns 0.022% of the company’s shares, worth ₩54.01M. The average tenure of the management team and the board of directors is 6.4 years and 1.3 years respectively.
Key information
Krinsky Hong
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.1yrs |
| CEO ownership | 0.02% |
| Management average tenure | 6.4yrs |
| Board average tenure | 1.3yrs |
Recent management updates
Recent updates
CEO
Krinsky Hong (62 yo)
Mr. Yoo Seok Hong, also known as Krinsky, is Director of Scioto Biosciences, Inc. from February 2025. He is Co-Chief Executive Officer of Genome & Company from May 2023 and is its Director. Yoo Seok Hong w...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Chief Executive Officer & Director | 3.1yrs | no data | 0.022% ₩ 54.0m | |
| Founder | 10.8yrs | no data | 6.94% ₩ 16.8b | |
| Founder | 10.8yrs | no data | 7.44% ₩ 18.0b | |
| CFO & Internal Accounting Manager | no data | no data | no data | |
| Head of Accounting | no data | no data | no data | |
| MD and Head of Pharmacology & Toxicology Research Lab | 6.4yrs | no data | no data | |
| MD & Head of Consumer Business Group | 4.4yrs | no data | no data |
Experienced Management: A314130's management team is seasoned and experienced (6.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Chief Executive Officer & Director | no data | no data | 0.022% ₩ 54.0m | |
| Founder | no data | no data | 6.94% ₩ 16.8b | |
| Founder | no data | no data | 7.44% ₩ 18.0b | |
| Independent Outside Director | less than a year | no data | no data | |
| Independent Outside Director | 1.3yrs | no data | no data | |
| Director | 1.4yrs | no data | no data | |
| Independent Outside Director | 1.3yrs | no data | no data |
Experienced Board: A314130's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/14 01:30 |
| End of Day Share Price | 2026/06/12 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genome & Company is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.